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Background: The yeast Saccharomyces boulardii is used worldwide as a probiotic to alleviate the effects of several
gastrointestinal diseases and control antibiotics-associated diarrhea. While many studies report the probiotic effects
of S. boulardii, no genome information for this yeast is currently available in the public domain.
Results: We report the 11.4 Mbp draft genome of this probiotic yeast. The draft genome was obtained by
assembling Roche 454 FLX + shotgun data into 194 contigs with an N50 of 251 Kbp. We compare our draft
genome with all other Saccharomyces cerevisiae genomes.
Conclusions: Our analysis confirms the close similarity of S. boulardii to S. cerevisiae strains and provides a framework
to understand the probiotic effects of this yeast, which exhibits unique physiological and metabolic properties.
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Probiotics are live microbes that assist in restoring the
symbiotic intestinal gut flora balance and thus bestow
health benefits to the host [1,2]. The most commonly
used human probiotics are members of the Lactobacillus
and Bifidobacterium species [3]. Besides these bacteria,
Saccharomyces boulardii (Sb), a yeast strain, is also widely
used as a probiotic to treat a variety of conditions [4]
including antibiotics-associated diarrhea and recurrent
Clostridium difficile infection. A primary advantage of
using Sb as a probiotic is that it can be used by patients
undergoing antibiotic regimen due to its natural resistance
to antibiotics [5]. The genetic transfer of antibiotic resist-
ance genes, a frequent event between pathogenic and
gastrointestinal tract (GIT) bacteria, is not as frequent
between yeast and bacteria [6,7]. Furthermore, Sb is also
tolerant to various local stresses such as the presence of
gastrointestinal (GI) enzymes, bile salts, organic acids etc.
and can withstand considerable variations in pH and
temperature while transiting through the human GIT [8].* Correspondence: krishna@imtech.res.in
†Equal contributors
CSIR-Institute of Microbial Technology, Chandigarh, India
© 2013 Khatri et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orSb is a tropical strain of yeast that is thermophilic and
mostly non-pathogenic to humans [5,9-12]. It was first
isolated from the skin of lychee and mangosteen fruits
in 1923 by the French scientist Henri Boulard in the
Indo-China region, and has since then shown to be effective
as a preventive and therapeutic agent for diarrhea and other
GI disorders caused by the administration of antimicrobial
agents [13]. The detailed and precise mechanisms of the
action of Sb to confer protection against several diseases
remain as yet unexplored although some specific proteins
have been suggested to play key roles in its probiotic func-
tion. For example, a 54 kDa serine protease from Sb was
reported to provide protection against C. difficile infections
by cleaving toxins A and B [14,15]. Similarly, a 120 kDa
protein has been suggested to play a role in neutralizing
the secretion induced by the cholera toxin by reducing
cyclic Adenosine Monophosphate (cAMP) levels [16]. Sb
can also inhibit the Escherichia coli endotoxin by dephos-
phorylation mediated by a 63 kDa protein phosphatase
[17]. Likewise, Sb can decrease IL-8 proinflammatory
cytokine secretion in Enterohemorrhagic E. coli (EHEC)
infections by inhibiting the NF-κB and Mitogen-Activated
Protein Kinase (MAPK) signaling pathways [18]. Sb hastd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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from GIT of mice [19] and can inhibit in vitro adhesion of
Entamoeba histolytica trophozoites to human erythrocytes
[20] and C. difficile adhesion to vero cells [21]. These
enteropathogens adhere to the host tissue surface as the
initial event for infecting the host. The outer membrane of
Sb which is particularly rich in mannose, as compared to
other yeasts, adheres to the enteropathogens strongly and
inhibits their binding to the mucous membrane of the
GIT [22].
The taxonomic position of Sb has been an issue of
intense debate [8]. Sb was initially suggested to be a new
species of the hemiascomycota genus Saccharomyces [23].
Based on comparative electrophoretic karyotyping and
multivariate analysis of the polymorphism observed in
pulsed-field gel electrophoresis Cardinali and Martini [24]
classified Sb outside of the S. cerevisiae group. However,
molecular phylogenetics and typing using molecular
techniques viz., species-specific polymerase chain reaction
(PCR), randomly amplified polymorphic DNA-PCR, re-
striction fragment length polymorphism analysis (RFLP)
of rDNA spacer region and pulsed field gel electrophoresis
(PFGE) helped identify Sb as a strain of S. cerevisiae
[25]. Moreover, comparative genomic hybridization
also established that S. cerevisiae and Sb are members
of the same species [25]. But, Sb differs from other S.
cerevisiae genetically as comparative genome hybridization
using oligonucleotide-based microarrays reveal trisomy of
chromosome IX and altered copy number of individual
genes [26]. When compared to S. cerevisiae strains S288c
and 1171 T there is 100% similarity in the D1/D2 domain
sequence of the 26S rDNA of eight Sb strains and more
than 95% similarity to mitochondrial cytochrome-c oxidase
II gene (COX2) sequences [27]. Another differentiating
criteria reported in literature is that Sb is incapable of
metabolizing galactose as a source of carbon [23,28].
However, McCullogh et al. (1998) [29] have shown that
galactose could be metabolized by some Sb strains.
Therefore, we determined the genome sequence of Sb in
order to get insights into the evolutionary history and
taxonomic position and to get a better understanding of
the various probiotic effects of this yeast, which exhibits
unique physiological and metabolic properties.
Methods
Isolation and purification of S. boulardii genomic DNA
A sachet of Dr. Reddy’s Laboratories Econorm 250 mg
(B. No. 1500, Mfg. Date: 05/12, Expiry Date: 04/14)
containing lyophilized cells of Sb was used as the source
of the probiotic yeast. Yeast cells were suspended in
Milli-Q water, serially diluted, and plated on Yeast Mold
(YM) agar (Difco) plates. The plates were incubated at
37°C for 48 hours. An isolated colony was picked from the
plate and cultured in Yeast Extract-Peptone-Dextrose(YEPD) broth (HIMEDIA) for 24 hours at 37°C in a rotary
shaker (180 RPM). The cells were centrifuged at 5000 g
for 10 minutes and washed with distilled water. DNA
isolation was performed using the ZR Fungal/Bacterial
DNA mini prep kit (Zymogen) as per instructions in its
user manual. After isolation, the genomic DNA was
treated with RNase A (1 μl of a 10 μg/mL stock solution
for 100 μl of solution containing DNA) and incubated at
37°C for 30 minutes. Then, 1/10 volume of 3 M sodium
acetate (pH 5.2) and 2.5 volumes of absolute ethanol
was added followed by incubation at −20°C overnight and
centrifugation at 14,000 rpm for 30 minutes at 4°C. Super-
natant was carefully discarded; pellet was rinsed with 70%
ethanol and centrifuged again at 14,000 rpm for 15 mi-
nutes at 4°C. The ratio of OD at 260/280 nm was ~1.8 as
observed by NanoDropND-1000 spectrophotometer.
Internal transcribed spacer-polymerase chain reaction
(ITS-PCR)
To amplify the ITS regions, primers ITS1 (TCCGTAGG
TGAACCTGCGG) and ITS4 (TCCTCCGCTTATTGAT
ATG) were used. Amplification was done using a mixture
containing 1× Standard Taq Reaction Buffer, dNTPs
(200 μM), BSA (0.3 μg/μL), template DNA (500 ng),
1.25 units/50 μl PCR Taq DNA Polymerase (Taq DNA
Polymerase with Standard Taq Buffer; New England
BioLabs) and forward and reverse primers (0.2 μM each).
The cycling parameters used for amplification were: initial
denaturation for 5 minutes at 95°C, followed by 30 cycles
of 30 seconds at 95°C, 30 seconds at 50°C and 90 seconds
at 72°C, with a final extension for 10 minutes at 72°C and
cooling to 4°C. The amplified products were separated on
1.2% agarose gels, visualized and photographed on an
Alpha Image Analyzer (Alpha Innotech Corporation, CA).
The DNA from the amplified bands was eluted with
QIAquick Gel Extraction Kit (Qiagen N.V.). The eluted
DNA was further amplified for sequencing using Termin-
ator Ready Reaction Mix (1 μl), Sequencing Buffer (1 μl;
5×; 200 mM Tris-Cl, 5 mM MgCl2, pH 9.0), PCR ampli-
fied DNA (35 ng), primer (3.2 pmol) and Milli-Q water to
make up the volume to 10 μl. PCR cycling conditions
were: initial denaturation for 1 minute at 96°C, followed
by 24 cycles of 10 seconds at 96°C, 5 seconds at 50°C and
4 minutes at 60°C and cooling to 4°C. The final PCR prod-
uct was sequenced on a Sanger sequencer and the resulting
ITS sequence was compared against all available ITS
sequences on the NCBI database.
Microsatellite fingerprinting
Microsatellite fingerprinting based on the Post Meiotic
Segregation (PMS) marker [30], PMS1, PMS2 and PMS3
was performed. Amplification was achieved using a mix-
ture containing 1× Standard Taq Reaction Buffer, dNTPs
(200 μM), BSA (0.3 μg/μL), template DNA (500 ng), 1.25
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ase with Standard Taq Buffer; New England BioLabs) and
0.2 μM of forward and reverse primers (PMS1: GTGG
TGGTGGTGGTG; PMS2: GACGACGACGACGAC and
PMS3: GACAGACAGACAGACA). The following cycling
parameters were used for microsatellite fingerprinting: ini-
tial denaturation for 5 minutes at 94°C, followed by 40 cy-
cles of 1 minute at 94°C, 2 minutes at 45°C and 3 minutes
at 72°C, with a final extension for 10 minutes at 72°C and
cooling to 4°C. The amplified products were separated on
1.2% agarose gels, visualized and photographed on an
Alpha Image Analyzer (Alpha Innotech Corporation, CA).
Genome sequencing
Sb EDRL (Econorm - Dr. Reddy’s Laboratories) was
sequenced using the 454/Roche GS FLX Titanium system.
Library preparation was carried out according to the GS
FLX Titanium Rapid Library Preparation Kit (Roche
Applied Sciences) at Centre for Cellular and Molecular
Platforms (C-CAMP), Bangalore, India. The genomic
DNA was first sheared into 400–1000 base-pair-long
fragments and its quality was assessed using a BioAnalyzer
DNA 7500 LabChip. Blunt ends were generated and
adaptor ligation was followed by removal of small frag-
ments. After library immobilization, the library was quan-
tified using the RiboGreen method and the final yield was
calculated. Half PicoTiter Plate of 454 shotgun sequencing
was performed and resulted in a total of 733,390 reads for
Sb EDRL with ~50× coverage.
Assembly, mapping and annotation
The 454 shotgun reads were assembled de novo using
Newbler v2 [31]. Multiple assemblies were obtained by
varying the parameters for the minimum overlap length
(ml) and minimum overlap identity (mi). The assembly
that contained the lowest number of contigs and best
N50 score (parameters: minlen 45; mi 96; ml 100) was
chosen for further analysis. The quality of the assembly
was further checked by mapping back the reads on the
draft genome and visually checking for errors. Feature
annotation was carried out by the MAKER pipeline [32]
and tRNA was predicted by tRNAscan-SE 1.23 [33]. Fea-
tures thus annotated were subjected to BLASTp [34] for
functional characterization of the proteins with an E-value
cutoff of 1e-5. In addition to de novo assembly, the 454
shotgun reads were mapped onto 34 draft and complete
genomes of S. cerevisiae available at NCBI (Additional
file 1) using the mapping algorithm of CLCbio Genomics
wb6 (www.clcbio.com).
Comparative genomics
The draft genome annotated by the MAKER [32] pipeline
and the reference-mapped genomes were searched for
the presence of proteins in the molecular weight rangeof 54 kDa and 120 kDa using an in-house Practical Extrac-
tion and Report Language (PERL) script. The 63 kDa pro-
tein was retrieved by BLASTp using as query a 38-amino
acid sequence stretch of this protein previously reported
in literature [17], and the molecular weight was further
confirmed using our PERL script. In order to narrow
down on the 54 kDa protease, proteins in the molecular
weight range 50–60 kDa, retrieved as mentioned above,
were subject to BLASTp against the MEROPS database
(http://merops.sanger.ac.uk/) and an independent hmmscan
[35] run against the protein family (PFAM) database [36]
with an E-value cutoff of 1e-5. These proteins were further
used as queries in the Fold and Function Assignment Sys-
tem (FFAS) [37] program to retrieve annotated homologs
and subjected to BLASTp against the Gene Ontology (GO)
database [38] with an E-value cutoff of 1e-5. Likewise, the
sequences of 119–121 kDa proteins obtained using our
PERL script was subjected to BLASTp against the GO
database with an E-value cutoff of 1e-5 and Search Tool
for the Retrieval of Interacting Genes/Proteins (STRING)
[39] analysis was performed to find interacting partners.
Galactose metabolizing enzymes of the Leloir pathway [40]
were found in the annotated genome by initiating stand-
alone BLASTp searches using sequences of these enzymes
from other S. cerevisiae.
Quality assurance
The genomic DNA was purified from a commercially
available lyophilized Sb (Econorm sachet; Dr. Reddy’s
Laboratories) and was further confirmed by ITS sequen-
cing. The ITS sequence was >99% identical to that of
the S. boulardii culture collection (KC2540481.1) strain.
PMS1, PMS2 and PMS3 markers were used to perform
microsatellite fingerprinting in order to verify the simi-
larity between Sb EDRL to other commercially available
Sb strains (Sb Uni-Sankyo Ltd. [Now known as Sanzyme
Ltd.] and Sb Kirkman) (Figure 1).
Results and discussion
Genome characteristics
Next-generation sequencing of Sb EDRL on the Roche
454 GS-FLX Titanium platform resulted in a total of
733,390 shotgun reads of length 40–1773 bp. High-quality
reads with ~50× coverage were assembled using Newbler
v2.8 to obtain a draft genome of 11.4 Mbp in 194 contigs
(N50: 251,807 bp). The GC content was 38% and 285
tRNA were present in Sb EDRL. Feature annotation was
performed using the MAKER pipeline with Augustus [41]
as the gene predictor. Of the 5803 coding sequences
(CDS) regions predicted, 4635 (79%) could find hits with
S. cerevisiae proteins when subject to a BLAST analysis
against the non-redundant (nr) database. Reference-based
mapping of Sb data onto other S. cerevisiae genomes
revealed that the maximum number of reads map to S.
Figure 1 Microsatellite fingerprinting of Sb: Microsatellite fingerprinting pattern for PMS molecular marker PMS1, PMS2 and PMS3;
where UNI - Sb Uni-Sankyo Ltd. (Now Sanzyme Ltd.); KIRK - Sb Kirkman; EDRL - Sb EDRL; and M- 1 kb DNA ladder.
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1a and S288c suggesting high similarity to these genomes
(Additional file 2).54-kDa serine protease and 120 kDa protein
Sb is being used in treatment of C. difficile-induced diar-
rhea and colitis [14]. Sb can inhibit the toxins A and B of C.
difficile by producing a 54 kDa serine protease that cleaves
these toxins [14,15]. Approximately 600 proteins of the Sb
genome in the molecular weight range of 50–60 kDa were
subjected to BLASTp against the MEROPS database and of
these, 221 hits were obtained. These proteins were further
subjected to BLASTp runs against the GO database [38].
Four proteins were found to be putative serine proteases
based on their GO annotation and presence of conserved
serine protease signature motifs. These four proteins belong
to the carboxypeptidase and subtilisin-like sub-classes of
serine protease (Additional file 2 and Additional file 3). In-
dependently, all the annotated proteins from the MAKER
pipeline were subjected to hmmscan against the PFAM
database. Twenty two serine proteases spanning 10 sub-
classes of the serine protease family were obtained. Of
these 22 proteins, 4 were in the molecular weight range of
50–60 kDa and were the same proteins identified by our
previous search against the MEROPS database as putative
serine proteases. It is therefore tempting to speculate that
one or more of these four proteins could possibly play a
role in cleaving the C. difficile toxins A and B.
A 120 kDa protein has been suggested to neutralize
the effects of cholera toxin by reducing cAMP levels in
mouse [17]. Fifteen proteins in the molecular weight
range of 119–121 kDa were retrieved (Additional file 3).
These proteins were subjected to BLASTp against the GO
database [38] with an E-value cutoff of 1e-5 and FFAS
search was performed. These 15 proteins mostly belong tothe family of kinases and transporters (Additional file 2).
The interacting partners of these proteins were fetched
out by STRING analysis (Additional file 2). It is possible
that any of these proteins may be involved in the cAMP
pathway to neutralize the effects of the cholera toxin.63-kDa phosphatase
A 63-kDa phosphatase of Sb (PHO8P) containing a peptide
of 38-amino acids (HFIGSSRTRSSDSLVTDSAAGATAFA
CALKSYNGAIGV), has been suggested to inhibit the tox-
icity of E. coli surface endotoxins by dephosphorylation
[18]. The sequence has an activation site (VTDSAAGAT)
that is present in S. cerevisiae and S. pombe. The presence
of this protein was examined in most of the S. cerevisiae
genomes available at the Saccharomyces genome database
(SGD) [42] and in our Sb genome. S. cerevisiae strains
AWRI1631, AWRI796, BY4741, BY4742, CBS7960, CEN.
PK113-7D, CLIB215, CLIB324, CLIB382, EC1118, EC9-8,
FL100, FostersB, FostersO, JAY291, Kyokai no.7, Lalvin
QA23, M22, PW5, RM11-1a, Sigma1278b, S288c, T73,
T7, UC5, Vin13, VL3, W303, Y10, YJM269, YJM789,
YPS163 and ZTW1 were considered, out of which the
phosphatase PHO8P was present in 28 strains and could
not be found in strains CLIB324, T73, Y10, CLIB382 and
M22. The pho8 gene is present in the Sb genome reported
here. Fourteen genes (prp3, jip4, YDR476C, snf1, snm1,
pex29, dig2, cwc21, kre2, vps52, vps72, vps60, rib3, pac11)
that are in the genomic neighborhood of the phosphatase
gene were analyzed. All these genes are completely con-
served in Sb, S288c, AWRI796, BY4741, BY4742, CEN.
PK113-7D, EC1118, FostersB, FostersO, JAY291, Kyokai
no. 7, Lalvin QA23, Sigma1278b, T7, Vin13, VL3, W303,
YJM789 and ZTW1 strains of S. cerevisiae (Figure 2A).
The S. cerevisiae RM11-1a (Figure 2K) has likewise all
genes conserved but they are present on the opposite
Figure 2 Genomic neighborhood of the 63 kDa phosphatase (PHO8) coding gene: (A) Sb EDRL, and S. cerevisiae strains S288c, AWRI796,
BY4741, BY4742, YJM789, Kyokai no. 7, EC1118, CEN.PK113-7D, FostersB, FostersO, JAY291, Lalvin QA23, Sigma1278b, T7, Vin13, VL3,
W303, YJM789, ZTW1; (B) S. cerevisiae strain PW5; (C) S. cerevisiae strain EC9-8; (D) S. cerevisiae strain YJM269; (E) S. cerevisiae strain
AWRI1631; (F) S. cerevisiae strain UC5; (G) S. cerevisiae strain YPS163; (H) S. cerevisiae strain FL100; (I) S. cerevisiae strain CBS7960; (J) S.
cerevisiae strain CLIB215; (K) S. cerevisiae strain RM11-1a. The genes mentioned are: prp3 (YDR473C, Pre-mRNA processing); jip4 (YDR475C, Jumonji
domain interacting protein); YDR476C (Putative protein of unknown function; Green fluorescent protein (GFP)-fusion protein localizes to the
endoplasmic reticulum); snf1 (YDR477W, Sucrose non-fermenting); snm1 (YDR478W, Suppressor of nuclear mitochondrial endoribonuclease 1); pex29
(YDR479C, Peroxisomal integral membrane peroxin); dig2 (YDR480W, Down-regulator of invasive growth); pho8p (YDR481C, Phosphate metabolism);
cwc21 (YDR482C, Complexed with Cef1p 1); kre2 (YDR483W, Killer toxin resistant); vps52 (YDR484W, Vacuolar protein sorting); vps72 (YDR485C, Vacuolar
protein sorting 1); vps60 (YDR486C, Vacuolar protein sorting); rib3 (YDR487C, Riboflavin biosynthesis); pac11 (YDR488C, Perish in the absence of CIN8 1).
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these 14 genes missing (Figure 2B-J). The protein was
conserved among all the S. cerevisiae strains with >95%
identity suggesting the possibility of phosphatase activity
in all the S. cerevisiae strains.
Galactose metabolism
One of the distinguishing features of Sb is that unlike S.
cerevisiae, it is incapable of utilizing galactose as a source
of carbon [23,28,29,40,43]. However there are reports
of some Sb strains, which can utilize galactose [29]. The
enzymes galactose-mutarotase, galactokinase, galactose-1-
phosphate uridyltransferase, UDP-galactose-4-epimerase
and phosphoglucomutase are constituents of the Leloir
pathway which helps to catalyze the conversion of galact-
ose to glucose-6-phosphate [29]. Glucose-6-phosphate can
then further be utilized via the glycolysis pathway.
Galactokinase, galactose-1-phosphate uridyltransferase
and UDP-galactose-4-epimerase are in synteny in most
of the S. cerevisiae strains such as RM11-1a, S288c,
AWRI796, BY4741, BY4742, Fosters B, FostersO, JAY291,
LalvinQA23, Sigma1278b, T7, UC5, Vin13, VL3, YJM789,
AWRI1631, CEN.PK113-7D, EC1118, Kyokai no. 7, ZTW1
and a similar synteny was observed for our Sb (Figure 3). S.cerevisiae strains CLIB382 and Y10 were not included in
this analysis as their genomes are not annotated completely
on the SGD. Surprisingly, our Sb genome has all the genes
responsible for galactose uptake and fermentation, although
it has been suggested that Sb is not able to utilize galactose
as a carbon source [28,44]. We have experimentally con-
firmed that Sb EDRL whose genome is reported here can
assimilate galactose but cannot ferment it (unpublished
results). Given that all genes responsible for galactose
assimilation and fermentation are present in our genome,
an effect similar to that observed by van den Brink et. al.,
2009 [45] for S. cerevisiae CEN.PK113-7D wherein the
yeast is unable to suddenly switch from glucose to galactose
in the absence of oxygen (fermentation), due to energetic
requirements, may help explain the inability of our Sb to
ferment galactose.
Future directions
The genome of Sb offers an important starting point to
glean insights into the probiotic effects of this yeast and
help differentiate it from other strains of S. cerevisiae. It
is possible that the various probiotic effects that have
been attributed to Sb do not necessarily correspond to
the same strain of this organism. Therefore it will be of
Figure 3 Leloir pathway genes for galactose metabolism: Genomic neighborhood of genes involved in galactose metabolism. (A) Sb
EDRL; (B) S. cerevisiae strains S288c, AWRI1631, AWRI796, BY4741, BY4742, CEN.PK113-7D, EC1118, FostersB, FostersO, JAY291, Kyokai no. 7, Lalvin
QA23, Sigma1278b, T7, UC5, Vin13, VL3, YJM789, W303, ZTW1; (C) S. cerevisiae strain FL100; (D) S. cerevisiae strain EC9-8; (E) S. cerevisiae strain PW5;
(F) S. cerevisiae strain CLIB324; (G) S. cerevisiae strain YJM269; (H) S. cerevisiae strain CLIB215; (I) S. cerevisiae strain CBS7960; (J) S. cerevisiae strain
M22; (K) S. cerevisiae strain YPS163; (L) S. cerevisiae strain T73; (M) S. cerevisiae strain RM11-1A. The genes shown are: YBR013C (Uncharacterized
ORF); grx7 (YBR014C, Glutaredoxin 2); mnn2 (YBR015C, Mannosyltransferase); YBR016W; kap104 (YBR017C, Karyopherin); gal1 (YBR020W,
Galactose metabolism); gal7 (YBR018C, Galactose metabolism); gal10 (YBR019C, Galactose metabolism); fur4 (YBR021W, 5-Fluorouridine
sensitivity); poa1 (YBR022W, Phosphatase Of ADP-ribose 1’-phosphate); chs3 (YBR023C, Chitin Synthase); sco2 (YBR024C, Suppressor of
Cytochrome oxidase deficiency); ola1 (YBR025C, Obg-like ATPase); rma1 (YKL132C, Reduced Mating A); she2 (YKL130C, Swi5p-dependent HO
Expression); myo3 (YKL129C, Myosin); pmu1 (YKL128C, Phosphomutase); pgm1 (YKL127W, Phosphoglucomutase); ypk1 (YKL126W, Yeast protein
kinase); rrn3 (YKL125W, Regulation of RNA Polymerase); ssh4 (YKL124W, Suppressor of SHr3 deletion); srt1 (YMR101C, Cis-prenyltransferase);
YMR102C; YMR103C; ypk2 (YMR104C, Yeast protein kinase); pgm2 (YMR105C, Phosphoglucomutase); yku80 (YMR106C, Yeast KU protein); spg4
(YMR107C, Stationary Phase gene).
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able strains of Sb in order to get a complete genome-level
understanding of this important probiotic yeast.
Conclusions
The first draft genome of Sb provides a framework to
understand at a molecular level, some of the properties
of this novel probiotic yeast. While it has been shownthat Sb strains do not utilize galactose [28], our genome
surprisingly reveals the conservation of all enzymes in-
volved in the Leloir pathway. In addition, we were able
to locate a 63 kDa phosphatase that has been suggested
to inhibit the toxicity of E. coli surface endotoxins [17].
Furthermore, we could shortlist putative candidates for
the 54 kDa serine protease and the 120 kDa protein that
confers additional probiotic functions to Sb. It is of
Khatri et al. Gut Pathogens 2013, 5:30 Page 7 of 8
http://www.gutpathogens.com/content/5/1/30interest to note that none of these proteins however are
unique to Sb and have close homologues in other strains
of S. cerevisiae.
Availability of supporting data
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The version described in this paper is the first version
ATCS01000000.
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Additional file 3: Protein sequences of putative 120 kDa proteins,
54 kDa serine proteases, 63 kDa phosphatase with its genomic
neighbors and proteins involved in galactose metabolism.
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